Lorenz Mayr joins Drug Discovery 2017 speaker lineup
Posted: 31 January 2017 | SMi Group | No comments yet
Lorenz Mayr, esteemed Vice President and Global Head of Biological Reagents and Assay Development at AstraZeneca will be joining the expert speaker lineup for the launch conference on Drug Discovery. The event takes place on 27 and 28 April 2017 in London.
With a focus on CRISPR/Cas9 technology, Lorenz’s keynote address will explore how this new emerging technique has become a pivotal new approach for drug discovery, particularly in target discovery, hit finding and translational studies. A few key points include:
- an overview of PGE and introduction to CRISPR/Cas9 technology
- applications in target finding, hit and lead discovery, efficacy and safety models
- AstraZeneca’s unique approach towards innovation and collaboration
- case studies from AstraZeneca’s drug discovery programme
- future outlook of PGE for drug discovery and therapeutic applications.
Lorenz will be speaking on Day 1 of the conference and joins lead decision-makers and industry innovators from Sanofi, Takeda, Merck Serono, AbbVie, GSK, Johnson & Johnson, UCB Pharma, Eli Lilly and more. A full list of speakers can be found on www.drug-discovery.co.uk/DTR.
SMi’s Drug Discovery conference aims to bridge the gaps in approval for drug discovery and development by discussing the latest scientific breakthroughs, exploring novel technologies and approaches that can be used to overcome drug development challenges.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
The event will also feature two post-conference workshops on new approaches in lead generation and applications of physicochemical and biomimetic properties in early drug discovery.
For more details about the conference and to register, visit www.drug-discovery.co.uk/DTR.
Drug Discovery
27 – 28 March2017
Holiday Inn Kensington Forum
www.drug-discovery.co.uk/DTR
Related topics
Drug Discovery, Hit-to-Lead, Translational Science
Related organisations
AbbVie, AstraZeneca, Merck KGaA, Sanofi, Takeda
Related people
Lorenz Mayr